Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of met... Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy. Mehr anzeigen
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results PR Newswire DUBLIN, Nov. 6, 2024 – 14% year-over-year revenue increase from combined key growth drivers:Xywav®, Epidiolex® and...
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic...
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024 PR Newswire DUBLIN, Oct. 23, 2024 DUBLIN, Oct. 23, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.65 | 2.2268907563 | 119 | 128.99 | 118.06 | 926707 | 126.13175306 | CS |
| 4 | 7.15 | 6.24454148472 | 114.5 | 128.99 | 107.44 | 636276 | 117.56981426 | CS |
| 12 | 7.16 | 6.25382129444 | 114.49 | 128.99 | 104.42 | 697254 | 112.46452183 | CS |
| 26 | 9.28 | 8.25843196583 | 112.37 | 128.99 | 99.06 | 717418 | 110.29297986 | CS |
| 52 | -2.61 | -2.10043457267 | 124.26 | 134.17 | 99.06 | 674303 | 114.32940029 | CS |
| 156 | -16.98 | -12.2484310755 | 138.63 | 169.98 | 99.06 | 598159 | 131.51804643 | CS |
| 260 | -12.68 | -9.43944018462 | 134.33 | 189 | 86.88 | 620807 | 136.0439116 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
